Skip to main content

Table 7 Hazard ratios (95% Confidence Intervals) of Outcomes in Matched Cohorts of Dabigatran and Rivaroxaban low and standard doses in Non-Valvular Atrial Fibrillation

From: Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

 Patients Eligible for low dose but taking standard dose vs. those taking low dosePatients Eligible for Standard dose but taking low dose vs. those taking dose standard dose
Received Low Dose
Events (Events/year)
Received Standard Dose
Events (Events/year)
95% Confidence Interval, p-valueReceived Low Dose
Events (Events/year)
Received Standard Dose
Events (Events/year)
95% Confidence Interval, p-value
Ischemic Stroke
 Dabigatran
Unadjusted25 (0.059)57 (0.043)0.77 (0.47–1.26; p = 0.3)59 (0.051)319 (0.042)1.2 (0.92–1.6, P = 0.17)
Propensity Matched22 (0.059)28 (0.061)1.13 (0.63–2; p = 0.69)55 (0.049)88 (0.071)0.74 (0.53–1.04; p = 0.08)
 Rivaroxaban
Unadjusted176 (0.057)161 (0.043)0.87 (0.7–1.1; p = 0.2)89 (0.040)256 (0.026)1.36 (1.07–1.7, P = 0.01)
Propensity Matched103 (0.048)128 (0.053)1.24 (0.96–1.6; p = 0.1)78 (0.040)73 (0.030)1.13 (0.83–1.56, P = 0.43)
Major Bleeding
 Dabigatran
Unadjusted62 (0.1456)124 (0.093)0.69 (0.51–0.94; p = 0.02)82 (0.071)393 (0.051)1.35 (1.06–1.7, p = 0.01)
Propensity Matched46 (0.1228)58 (0.1258)1.07 (0.7–1.58 P = 0.75)78 (0.069)92 (0.075)1.01 (0.74–1.37, P = 0.97)
 Rivaroxaban
Unadjusted307 (0.099)294 (0.079)0.95 (0.8–1.1, P = 0.5)147 (0.067)426 (0.043)1.35 (1.12–1.6, P = 0.001)
Propensity Matched197 (0.091)216 (0.089)1.12 (0.92–1.35, P = 0.26)131 (0.068)116 (0.048)1.2 (0.93–1.53, P = 0.21)
GI Hemorrhage
 Dabigatran
Unadjusted46 (0.108)100(0.075)0.75 (0.5–1.07, P = 0.1)67 (0.058)292 (0.038)1.47 (1.13–1.9, P = 0005)
Propensity Matched33 (0.088)45 (0.098)1.16 (0.74–1.82, P = 0.53)63 (0.056)68 (0.055)1.08 (0.77–1.53, P = 0.66)
 Rivaroxaban
Unadjusted243 (0.078)227 (0.061)0.93 (0.78–1.1, P = 0.4)111 (0.050)341 (0.034)1.28 (1.04–1.6, P = 0.02)
Propensity Matched158 (0.073)166 (0.069)1.07 (0.86–1.32, P = 0.5)97 (0.050)96 (0.040)1.08 (0.82–1.43, P = 0.58)
Intracranial Hemorrhage
 Dabigatran
Unadjusted< 11< 110.33 (0.12–0.9; p = 0.03)< 1152 (0.007)0.77 (0.33–1.8; p = 0.54)
Propensity Matched< 11< 110.63 (0.2–1.99; p = 0.43)< 1112(0.009)0.58 (0.22–1.54; p = 0.27)
 Rivaroxaban
Unadjusted25 (0.008)26 (0.007)0.99 (0.57–1.7; p = 0.96)13 (0.006)38 (0.004)1.33 (0.7–2.5; p = 0.37)
Propensity Matched17 (0.008)22 (0.009)1.26 (0.67–2.38; p = 0.47)12 (0.006)< 111.57 (0.64–3.84; p = 0.32)